Compare ELVR & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVR | CTMX |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.4M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | ELVR | CTMX |
|---|---|---|
| Price | $41.35 | $3.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 169.8K | ★ 2.4M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $146,440,045.00 | $113,631,000.00 |
| Revenue This Year | $11.13 | N/A |
| Revenue Next Year | $13.58 | N/A |
| P/E Ratio | ★ N/A | $16.28 |
| Revenue Growth | ★ 11.20 | N/A |
| 52 Week Low | $15.55 | $0.40 |
| 52 Week High | $41.55 | $4.62 |
| Indicator | ELVR | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.40 |
| Support Level | N/A | $3.66 |
| Resistance Level | N/A | $4.20 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 43.84 |
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.